Identification of a critical dose level for risk assessment: Developments in benchmark dose analysis of continuous endpoints

Toxicological Sciences

Volumn 90, Issue 1, 2006, Pages 241-251

  Sand, Salomon ^a   von Rosen, Dietrich ^b   Victorin, Katarina ^a   Falk Filipsson, Agneta ^c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^c Swedish Chemicals Agency   (Sweden)

Author keywords

Benchmark dose; BMD; Dose response; Gompertz model; Hill function; Richards function; Risk assessment

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; RETINOL PALMITATE; RETINOL STEARATE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE DENSITY; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DRUG SURVEILLANCE PROGRAM; FEMALE; INTERMETHOD COMPARISON; LIVER WEIGHT; LONG TERM EXPOSURE; LOW DRUG DOSE; MATHEMATICAL ANALYSIS; METHODOLOGY; NONHUMAN; ORGAN WEIGHT; QUALITY CONTROL; RAT; RISK ASSESSMENT; STATISTICAL MODEL; THYMUS; TOXICOLOGICAL PARAMETERS;

ANIMALS; BENCHMARKING; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MODELS, STATISTICAL; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RATS; RATS, LONG-EVANS; RATS, WISTAR; RISK ASSESSMENT; XENOBIOTICS;

ANIMALIA;

EID: 33144462622     PISSN: 10966080     EISSN: None     Source Type: Journal    
DOI: 10.1093/toxsci/kfj057     Document Type: Article

References (41)

1. Allen, B. C., Kavlock, R. J., Kimmel, C. A., and Faustman, E. M. (1994). Dose-response assessment for developmental toxicity. II. Comparison of generic benchmark dose estimates with no observed adverse effect levels. Fundam. Appl. Toxicol. 23, 487-495.
2. Allen, B. C., Strong, P. L., Price, C. J., Hubbard, S. A., and Daston, G. P. (1996). Benchmark dose analysis of developmental toxicity in rats exposed to boric acid. Fundam. Appl. Toxicol. 32, 194-204.
3. Allen, B. C., Gentry, R., Shipp, A., and Van Landingham, C. (1998). Calculation of benchmark doses for reproductive and developmental toxicity observed after exposure to isopropanol. Regul. Toxicol. Pharmacol. 28, 38-44.
4. Barnes, D., Datson, P., Evans, J., Jarabek, A., Kavlock, R., Kimmel, C., Park, C., and Spitzer, H. (1995). Benchmark dose workshop: Criteria for use of a benchmark dose to estimate a reference dose. Regul. Toxicol. Pharmacol. 21, 296-306.
5. Barton, H. A., and Das, S. (1996). Alternatives for a risk assessment on chronic noncancer effects from oral exposure to trichloroethylene. Regul. Toxicol. Pharmacol. 24, 269-285.
6. Barton, H. A., Andersen, M. E., and Allen, B. C. (1998). Dose-response characteristics of uterine responses in rats exposed to estrogen agonists. Regul. Toxicol. Pharmacol. 28, 133-149.
7. Cornish-Bowden, A. (1995). Fundamentals of Enzyme Kinetics. Portland Press Ltd., London.
8. Crump, K. (1984). A new method for determining allowable daily intakes. Fundam. Appl. Toxicol. 4, 854-871.
9. Crump, K. (1995). Calculation of benchmark doses from continuous data. Risk Anal. 15, 79-89.
10. Dekkers, S., de Heer, C., and Rennen, M. A. (2001). Critical effect sizes in toxicological risk assessment: A comprehensive and critical evaluation. Environ. Toxicol. Pharmacol. 10, 33-52.
11. Dybing, E., Doe, J., Groten, J., Kleiner, J., O'Brien, J., Renwick, A. G., Schlatter, J., Steinberg, P., Tritscher, A., Walker, R., et al. (2002). Hazard characterisation of chemicals in food and diet: Dose response, mechanisms and extrapolation issues. Food Chem. Toxicol. 40, 237-282.
12. Edler, L., Poirier, K., Dourson, M., Kleiner, J., Mileson, B., Nordmann, H., Renwick, A., Slob, W., Walton, K., and Wurtzen, G. (2002). Mathematical modeling and quantitative methods. Food Chem. Toxicol. 40, 283-326.
13. Falk Filipsson, A., Sand, S., Nilsson, J., Victorin, K. (2003). The benchmark dose method - Review of available models, and recommendations for application in heath risk assessment. Crit. Rew. Toxicol. 33, 505-542.
14. Fletcher, N., Giese, N., Schmidt, C., Stern, N., Lind, P. M., Viluksela, M., Tuomisto, J. T., Tuomisto, J., Nau, H., and Håkansson, H. (2005). Altered retinoid metabolism in female Long-Evans and Han/Wistar rats following long-term 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-treatment. Toxicol. Sci. 86, 264-272.
15. Gaylor, D. W., and Aylward, L. L. (2004). An evaluation of benchmark dose methodology for non-cancer continuous-data health effects in animals due to exposures to dioxin (TCDD). Regul. Toxicol. Pharmacol. 40, 9-17.
16. Gaylor, D. W., and Slikker, W. (1990). Risk assessment for neurotoxic effects. Neurotoxicology 11, 211-218.
17. Gaylor, D., Ryan, L., Krewski, D., and Zhu, Y. (1998). Procedures for calculating benchmark doses for health risk assessment. Regul. Toxicol. Pharmacol. 28, 150-164.
18. Gaylor, D. W., and Slikker, W. (2004). Role of the standard deviation in the estimation of benchmark doses with continuous data. Risk Anal. 6, 1683-1687.
19. Giraldo, J., Vivas, N. M., Vila, E., and Badia, A. (2002). Assessing the (a)symmetry of concentration-effect curves: Empirical versus mechanistic models. Pharmacol. Ther. 95, 21-45.
20. Jämsä, T., Viluksela, M., Tuomisto, J. T., Tuomisto, J., and Tuukkanen, J. (2001). Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on bone in two rat strains with different aryl hydrocarbon receptor structures. J. Bone Miner. Res. 16, 1812-1820.
21. Kalliomaa, K., Haag-Gronlund, M., and Victorin, K. (1998). A new model function for continuous data sets in health risk assessment of chemicals using the benchmark dose concept. Regul. Toxicol. Pharmacol. 27, 98-107.
22. Kavlock, R. J., Allen, B. C., Faustman, E. M., and Kimmel, C. A. (1995). Dose-response assessments for developmental toxicity. IV. Benchmark doses for fetal weight changes. Fundam. Appl. Toxicol. 26, 211-222.
23. Kim, A. H., Kohn, M. C., Portier, C. J., and Walker, N. J. (2002). Impact of physiologically based pharmacokinetic modeling on benchmark dose calculations for TCDD-induced biochemical responses. Regul. Toxicol. Pharmacol. 36, 287-296.
24. Kodell, R. L., and West, R. W. (1993). Upper confidence limits on excess risk for quantitative responses. Risk Anal. 13, 177-182.
25. Murrell, J. A., Portier, C. J., and Morris, R. W. (1998). Characterizing dose-response I: Critical assessment of the benchmark dose concept. Risk Anal. 18, 13-26.
26. Richards, F. J. (1959). A flexible growth function for empirical use. J. Exp. Botany 10, 290-300.
27. Sand, S., Falk Filipsson, A., and Victorin, K. (2002). Evaluation of the benchmark dose method for dichotomous data: Model dependence and model selection. Regul. Toxicol. Pharmacol. 36, 184-197.
28. Sand, S., von Rosen, D., and Falk Filipsson, A. (2003). Benchmark calculations in risk assessment using continuous dose response information: The influence of variance and the determination of a cut-off value. Risk Anal. 23, 1059-1068
29. Sand, S., von Rosen, D., Eriksson, P., Fredriksson, A., Viberg, H., Victorin, K., and Falk Filipsson, A. (2004). Dose-response modeling and benchmark calculations from spontaneous behavior data on mice neonatally exposed to 2,2′,4,4′,5-pentabromodiphenyl ether. Toxicol. Sci. 81, 491-501.
30. Setzer, R.W., and Kimmel, C. A. (2003). Use of NOAEL, benchmark dose, and other models for human risk assessment of hormonally active substances. Pure Appl. Chem. 75, 2151-2158.
31. Slikker, W., Andersen, M. E., Bogdanffy, M. S., Bus, J. S., Cohen, S. D., Conolly, R. B., David, R. M., Doerrer, N. G., Dorman, D. C., Gaylor, D. W., et al. (2004a). Dose-dependent transitions in mechanisms of toxicity. Toxicol. Appl. Pharmacol. 201, 203-225.
32. Slikker, W., Andersen, M. E., Bogdanffy, M. S., Bus, J. S., Cohen, S. D., Conolly, R. B., David, R. M., Doerrer, N. G., Dorman, D. C., Gaylor, D. W., et al. (2004b). Dose-dependent transitions in mechanisms of toxicity: Case studies. Toxicol. Appl. Pharmacol. 201, 226-294.
33. Slob, W., and Pieters, M. N. (1998). A probabilistic approach for deriving acceptable human intake limits and human health risks from toxicological studies: General framework. Risk Anal. 18, 787-798.
34. Slob, W. (2002). Dose-response modeling of continuous endpoints. Toxicol. Sci. 66, 298-312.
35. Slob, W., Moerbeek, M., Rauniomaa, E., and Piersma, A. H. (2005). A statistical evaluation of toxicity study designs for the estimation of the benchmark dose in continuous endpoints. Toxicol. Sci. 84, 167-185.
36. Stiteler, W. M., and Swartout, J. (1991). Some statistical issues relating to the evaluations of risk levels at hazardous waste sites. Proceedings of the Section on Statistics and the Environment, ASA. American Statistical Association, Alexandria, VA, 39-43.
37. Toyoshiba, H., Walker, N. J., Bailer, A. J., and Portier, C. J. (2004). Evaluation of toxic equivalency factors for induction of cytochromes P450 CYP1A1 and CYP1A2 enzyme activity by dioxin-like compounds. Toxicol. Appl. Pharmacol. 194, 156-168.
38. U.S. Environmental Protection Agency (USEPA). (1995). The Use of the Benchmark Dose (BMD) Approach in Health Risk Assessment. Final report. EPA/630/R-94/007. Risk Assessment Forum, U.S. Environmental Protection Agency, Washington, DC.
39. U.S. Environmental Protection Agency (USEPA). (2005). The benchmark dose software (BMDS), version 1.3.2. Available at: http://cfpub.epa.gov/ncea/
40. Viluksela, M., Bager, Y., Tuomisto, J. T., Scheu, G., Unkila, M., Pohjanvirta, R., Flodström, S., Kosma, V., Mäki-Paakkanen, J., Vartiainen, T., et al. (2000). Liver tumor-promoting activity of 2,3,7,8-tetrachlodibenzo-p-dioxin (TCDD) in TCDD-sensitive and TCDD-resistant rat strains. Cancer Res. 60, 6911-6920.
41. West, R. W., and Kodell, R. L. (1993). Statistical methods of risk assessment for continuous variables. Commun Statist-Theory Meth. 22, 3363-3376.